Inhouse product
The mechanism of action of Mesalamine is unknown, but appears to be topical rather than systemic. Mucosal production of Arachidonic Acid metabolites, both through the cyclooxygenase pathways, that is, prostanoids, and through the lipoxygenase pathways, that is, leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic infammatory bowel disease. Mesalamine diminishes infammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
Weight Group (kg) | Morning Dosage | Evening Dosage | Duration |
17 to <33 | two 400 mg tablets | one 400 mg tablet | 6 weeks |
33 to <54 | three 400 mg tablets | two 400 mg tablets |
Hypersensitivity to salicylates or to any other component of the formulation.
The commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc.
It should be given in pregnancy only if the potential beneft justifes the potential risk to the fetus. Caution is advised when it is administered to a nursing mother.
Store below 30 0 C. Protect from light and moisture. Keep all medicines out of the reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet